Literature DB >> 29492854

Evolution of Antibiotic Use and Cost in Patients with Community-Acquired Pneumonia.

Sergio Sabbatani1, Raffaella Cesari2, Emanuela Pipitone3.   

Abstract

OBJECTIVE: To investigate the evolution and efficiency of the clinical management (particularly shift therapy) of patients with community-acquired pneumonia (CAP) in a hospital setting. STUDY DESIGN AND METHODS: This was a retrospective analysis of 120 hospitalised patients who were treated with antibiotics for CAP in the first semesters of 1999 (50 patients), 2000 (39 patients) and 2001 (31 patients). We evaluated the prescribed daily dose and the average hospitalisation and treatment periods for each drug. Pareto curves were used to examine relative costs and quantities of drugs administered. Total therapy costs and average cost for an antibiotic were also calculated.
RESULTS: Over the 3 years, the drugs most commonly used were ceftriaxone and ciprofloxacin; levofloxacin, introduced in 2001, allowed for shorter average treatment periods. Twenty-one of 39 (53.8%) patients seen in the first semester of 2000 were discharged early compared with 29 of 31 (93.54%) in 2001. Therapy was continued at home (shift therapy) with ciprofloxacin (n = 8), ceftriaxone (n = 5) and cotrimoxazole (n = 2) in 2000 and with ceftriaxone (n = 15), oral ciprofloxacin (n = 7) and oral levofloxacin (n = 7) in 2001.
CONCLUSIONS: Shift therapy using either oral or injectable antibiotics is possible in patients with CAP and allowed us to realise significant savings in management. Selection of route of administration of shift therapy should be made on an individual basis.

Entities:  

Keywords:  Ceftriaxone; Family Physician; Levofloxacin; Pareto Curve; Respective Cost

Year:  2002        PMID: 29492854     DOI: 10.2165/00044011-200222090-00005

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  9 in total

1.  Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention.

Authors:  M S Niederman; L A Mandell; A Anzueto; J B Bass; W A Broughton; G D Campbell; N Dean; T File; M J Fine; P A Gross; F Martinez; T J Marrie; J F Plouffe; J Ramirez; G A Sarosi; A Torres; R Wilson; V L Yu
Journal:  Am J Respir Crit Care Med       Date:  2001-06       Impact factor: 21.405

2.  Susceptibility of Streptococcus pneumoniae strains isolated in Italy to penicillin and ten other antibiotics.

Authors:  A Marchese; E A Debbia; A Arvigo; A Pesce; G C Schito
Journal:  J Antimicrob Chemother       Date:  1995-11       Impact factor: 5.790

3.  Incidence and prevalence as used in the analysis of the occurrence of nosocomial infections.

Authors:  F S Rhame; W D Sudderth
Journal:  Am J Epidemiol       Date:  1981-01       Impact factor: 4.897

4.  The management of infections and antibiotic therapy: a European survey.

Authors:  G A Halls
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

5.  Home intravenous antibiotic therapy (HIVAT): indications, patients and antimicrobial agents.

Authors:  D N Williams
Journal:  Int J Antimicrob Agents       Date:  1995-01       Impact factor: 5.283

Review 6.  [Role of parenteral cephalosporins for outpatients treatment of infections].

Authors:  S Esposito; T Mazzei; A Novelli
Journal:  Infez Med       Date:  2001-12

Review 7.  [Outpatient parenteral antibiotic treatment: the Italian model].

Authors:  S Esposito
Journal:  Infez Med       Date:  2001-03

8.  An international survey of the prevalence of hospital-acquired infection.

Authors:  R T Mayon-White; G Ducel; T Kereselidze; E Tikomirov
Journal:  J Hosp Infect       Date:  1988-02       Impact factor: 3.926

9.  National prevalence survey of hospital-acquired infections in Italy, 1983.

Authors:  M L Moro; M A Stazi; G Marasca; D Greco; A Zampieri
Journal:  J Hosp Infect       Date:  1986-07       Impact factor: 3.926

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.